Documenting controlled substance prescribing in psychiatry

By Selam Koch, PMHNP-BC, founder of OneStep Scribe and practicing psychiatric nurse practitioner. Published August 2026.

A controlled substance prescription is the entry in your chart most likely to be read by someone who was not in the room: a pharmacist, a covering colleague, a state monitoring program reviewer, a licensing board, sometimes counsel. It has to be legible to a stranger, two years later, who wants one thing: why this medication, at this dose, for this person, and what were you watching?

One caveat governs everything below and is stated once rather than section by section. This guide does not state the law of any state. Requirements for prescription drug monitoring program (PDMP) queries, quantity limits, agreements, toxicology testing and telehealth prescribing vary by state, schedule and substance, and they change. Verify federal requirements with current DEA and CMS guidance and state requirements with your controlling agency and licensing board.

Two things to confirm first

Your own authority. APRN controlled substance authority varies by state, and some states restrict or condition Schedule II prescribing. Your DEA registration is tied to a registered location, and many states require a separate state controlled substance registration. If you treat patients in more than one state, confirm what each state requires of you, not only of the prescription.

Your prescribing route. Controlled substances covered under Medicare Part D must generally be prescribed electronically under the SUPPORT Act, with narrow exceptions and CMS compliance measures in place. Confirm current CMS policy and that your platform is enabled for controlled substances.

The baseline record

Diagnosis justification that stands on its own

The weakest controlled substance charts I have reviewed share one feature: the diagnosis appears as a code and never as an argument. For a stimulant the record should carry developmental onset, symptoms in more than one setting, impairment described concretely, and the differential you set aside. That structure is laid out in adult ADHD evaluation and documentation. For a benzodiazepine, "anxiety" is not a justification. And a response to a trial is not a diagnosis: write the reasoning before the trial, not backward from it.

Prior trials, in specifics

"Failed multiple medications" is unusable. The record needs agent, dose reached, time at that dose, outcome and reason stopped. Intolerance at a low dose is a different story from non-response at a full trial.

Risk, misuse and diversion screening

Screen everyone, document that you screened everyone, and record the negatives as well as the positives. Screening based on how a patient looks or where they live is clinically unreliable and inequitable, and it leaves you without a comparable baseline for most of your panel. See documenting AUDIT-C and DAST-10 for structured results without a form dump.

For sedatives, and for anyone with a mood disorder, add a current suicide risk assessment with the reasoning behind your formulation, not just a score, plus the safety plan and crisis contacts you gave the patient, including the 988 Suicide and Crisis Lifeline. See suicide risk assessment documentation.

Consent that reflects a conversation

The consent entry should show what was discussed, not that a form was signed: dependence and tolerance, withdrawal risk and why abrupt discontinuation is not a plan, driving, interaction with alcohol and other sedatives, appetite and sleep, cardiovascular considerations for stimulants, pregnancy where relevant, and storage.

Name toxicology testing at baseline too: whether testing is part of care, when it will be requested, and how results will be used. A patient who learns testing exists only after an unexpected result is a consent gap, and in some states a specific-consent gap.

For a patient under 18, consent comes from the legal guardian. The chart should also show the youth's assent, who holds decision-making authority where custody is shared, and where the medication is kept relative to siblings and the school day.

PDMP checks: document the act, not the conclusion alone

A PDMP query is a clinical action. Chart that you queried and when, that you reviewed it yourself or who reviewed it if your state permits a delegate, what you found, and what you made of it. A bare checkbox may satisfy a state mandate, but a later reader cannot tell whether you reviewed an unremarkable report or never opened one. Record what you saw, within what your program's terms allow.

Agreements: what they should and should not claim

A written agreement is a communication tool. At its best it sets expectations in plain language before anyone is upset: one prescriber for this class, one pharmacy where practical, how prescriptions are timed and requested, the visit cadence required to continue, storage, what happens if a prescription is lost, and what monitoring you will do, including whether toxicology testing is part of care.

An agreement should not substitute for informed consent, frame the patient as a suspect, or imply a legal outcome. It should not set out conditions under which care ends: ending or conditioning a treatment relationship engages state abandonment standards, board rules and often payer contracts, and notice and referral obligations differ by state. Do not draft that language from a guide. And do not commit to what you will not do: if the agreement says you query the PDMP every visit, three visits and one query contradict your own document.

The follow-up visit

Each ongoing visit should leave behind:

• Adherence in specifics. Doses taken, doses missed, any self-adjustment and why.
• Function, not just symptoms. What is different at work, at home, in sleep. This is what justifies continuing.
• Objective anchors. Weight, blood pressure and pulse for stimulants; gait, sedation and cognition for sedatives.
• Fill history. Last fill date, days supply, any request ahead of the earliest permissible fill date.
• PDMP review at the cadence your state requires.
• Dose decisions with reasoning, including the decision not to change.

The prescription itself

Federal rules permit an individual practitioner to issue multiple Schedule II prescriptions at one visit covering up to a 90-day total supply, with the earliest permissible fill date written on the prescriptions after the first. Schedule II prescriptions cannot carry refills at all, so "no refills" is not a meaningful entry and "requested a refill" does not match the schedule: write "requested a new prescription." Refill language belongs in a Schedule IV benzodiazepine chart.

What this documentation does for level selection

These visits are routinely overcoded on the assumption that a scheduled drug makes the encounter complex. Three points, paraphrasing the code set:

• Prescription drug management sits at moderate risk in the medical decision making table. A scheduled drug does not by itself make a visit high complexity.
• The high-risk element clinicians reach for, drug therapy needing intensive monitoring for toxicity, is narrow. The monitoring must be for an adverse effect rather than for efficacy, and monitoring by history or examination does not count. A lithium level or a clozapine neutrophil count fits; routine stimulant weight and vital signs generally do not.
• PDMP review by the billing clinician on the encounter date counts toward total time when the level is selected on time. Delegate review does not, and review on another date does not.

Tapers, declining to continue, and red flags

Two things go wrong here. The first is silence: something concerning happens and the note records the outcome without the reasoning. The second is tone. Avoid labels that assign motive, slang for a sample, and wording that implies disbelief.

Three things the table cannot decide for you. Whether a bridge supply is appropriate, and whether it is permissible without a current evaluation, depends on the schedule and your state's rules. Early fill limits are set by state and payer rules, not clinician discretion. And this between-visit work is not an office visit: a request handled by phone or portal is not separately reportable.

When you decline to continue or taper

The note should show the clinical reasoning, what you offered in its place, the taper plan, what you said about withdrawal, whether a substance use disorder was identified and how it is being treated, and that care is continuing. Chart the conversation too, including any request for a second opinion.

Telehealth and controlled substances

This is where remembered rules are most likely to be wrong. The federal framework for prescribing controlled substances by telemedicine has been extended and revised repeatedly, with different provisions for different schedules. Do not rely on what was true last year, or on a blog post, including this one.

Modality is not only a charting detail. The federal provisions are generally framed around real-time, two-way audio-video communication, and audio-only prescribing is permitted only in narrow circumstances that depend on the substance. If a visit was audio only, confirm the current federal and state position before prescribing, not after.

What belongs in the telehealth note:

• Modality used, and if audio only, the basis on which prescribing was permissible.
• The patient's physical location at the time of the visit, and that you confirmed rather than assumed it.
• Your own location, and your licensure and any controlled substance registration in the state where the patient is located. Both follow the patient's location, not yours.
• How you verified identity, and who else was present.
• The dispensing pharmacy, and the basis on which prescribing is permissible, with the date you verified it.

The rules change, so a chart showing what you checked and when is more informative than one showing what you assumed. It does not make the prescribing correct. Place of service and modifier use are covered in telehealth psychiatry documentation.

Frequently asked questions

Does a signed agreement need to be renewed every year?

There is no single answer, and whether an agreement is required at all varies. Treat renewal as clinical rather than administrative: if the plan, the risk picture, the medication or the monitoring has changed, the agreement is out of date whatever its signature date.

What if the patient asks me not to document their substance use history?

Ask what specifically worries them, since it is usually disclosure to family, an employer or an insurer rather than the record itself. Then be accurate about access rather than reassuring. Substance use information can carry confidentiality protections beyond those covering the rest of the record, and those rules and their redisclosure limits differ by state and setting; records from a federally assisted substance use disorder program carry additional restrictions under 42 CFR Part 2. Check before you answer, then document what is necessary for safe prescribing.

What do I write when a patient declines toxicology testing?

Write the request, the reason given, what you explained, and what you decided as a result. A decline is information, not a finding, and a note that treats it as evidence of misuse reads badly to the patient and to the next clinician.

Related guides

• Substance Use Screening Documentation in a Psychiatric Visit: What to Capture, MDM Support, and Coding Implications
• Documenting an adult ADHD evaluation: the workup, the DSM-5-TR criteria, and the note that supports the diagnosis
• Documenting medication informed consent in psychiatry: what the note has to show
• Telehealth psychiatry documentation: POS codes, modifiers, and what your note must show
• Suicide risk assessment documentation: what a defensible, clinically useful note contains

This article is educational and reflects one clinician's understanding of coding rules at the time of writing. It is not legal, billing, or payer-specific advice, and it does not guarantee reimbursement or audit outcomes. Coding rules, payer policies, and state and federal laws change; always verify current requirements with your payers, coding resources, and compliance advisors, and consult your licensing board(s), current DEA guidance, and a healthcare attorney for licensure, consent, and controlled-substance questions. CPT is a registered trademark of the American Medical Association.